Abstract
Inflammatory bowel disease (IBD) is an idiopathic chronic, relapsing inflammation of the bowel which is caused by dysregulation of the mucosal immune system. Polyphenols as the secondary plant metabolites universally present in vegetables and fruits and are the most abundant antioxidants in the human diet. There is evidence demonstrating the beneficial health effects of dietary polyphenols. This review criticizes the potential of commonly used polyphenols including apple polyphenol, bilberry anthocyanin, curcumin, epigallocatechin-3-gallate (EGCG) and green tea polyphenols, naringenin, olive oil polyphenols, pomegranate polyphenols and ellagic acid, quercetin, as well as resveratrol specifically in IBD with an emphasis on cellular mechanisms and pharmaceutical aspects. Scientific research confirmed that dietary polyphenols possess both protective and therapeutic effects in the management of IBD mediated via down-regulation of inflammatory cytokines and enzymes, enhancing antioxidant defense, and suppressing inflammatory pathways and their cellular signaling mechanisms. Further preclinical and clinical studies are needed in order to understand safety, bioavailability and bioefficacy of dietary polyphenols in IBD patients.
Keywords: Inflammatory bowel disease, polyphenols, review.
Current Pharmaceutical Biotechnology
Title:The Role of Dietary Polyphenols in the Management of Inflammatory Bowel Disease
Volume: 16 Issue: 3
Author(s): Mohammad H. Farzaei, Roja Rahimi and Mohammad Abdollahi
Affiliation:
Keywords: Inflammatory bowel disease, polyphenols, review.
Abstract: Inflammatory bowel disease (IBD) is an idiopathic chronic, relapsing inflammation of the bowel which is caused by dysregulation of the mucosal immune system. Polyphenols as the secondary plant metabolites universally present in vegetables and fruits and are the most abundant antioxidants in the human diet. There is evidence demonstrating the beneficial health effects of dietary polyphenols. This review criticizes the potential of commonly used polyphenols including apple polyphenol, bilberry anthocyanin, curcumin, epigallocatechin-3-gallate (EGCG) and green tea polyphenols, naringenin, olive oil polyphenols, pomegranate polyphenols and ellagic acid, quercetin, as well as resveratrol specifically in IBD with an emphasis on cellular mechanisms and pharmaceutical aspects. Scientific research confirmed that dietary polyphenols possess both protective and therapeutic effects in the management of IBD mediated via down-regulation of inflammatory cytokines and enzymes, enhancing antioxidant defense, and suppressing inflammatory pathways and their cellular signaling mechanisms. Further preclinical and clinical studies are needed in order to understand safety, bioavailability and bioefficacy of dietary polyphenols in IBD patients.
Export Options
About this article
Cite this article as:
Farzaei H. Mohammad, Rahimi Roja and Abdollahi Mohammad, The Role of Dietary Polyphenols in the Management of Inflammatory Bowel Disease, Current Pharmaceutical Biotechnology 2015; 16 (3) . https://dx.doi.org/10.2174/1389201016666150118131704
DOI https://dx.doi.org/10.2174/1389201016666150118131704 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synergistic Interaction of Telomerase-Specific Oncolytic Virotherapy and Chemotherapeutic Agents for Human Cancer
Current Pharmaceutical Biotechnology Epigenetic Regulation and Therapeutic Approaches in Cancer
Current Topics in Medicinal Chemistry The Recombinant T Cell Receptor Strategy: Insights into Structure and Function of Recombinant Immunoreceptors on the Way Towards an Optimal Receptor Design for Cellular Immunotherapy
Current Gene Therapy Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges
Current Medicinal Chemistry Chemotherapeutic Options for Colorectal Cancer Patients with Cardiovascular Diseases.
Reviews on Recent Clinical Trials Cyclopentenyl Cytosine (CPEC): An Overview of its in vitro and in vivo Activity
Current Cancer Drug Targets TRPA1 and TRPM8 Receptors May Promote Local Vasodilation that Aggravates Oxaliplatin-Induced Peripheral Neuropathy Amenable to 17β-Estradiol Treatment
Current Neurovascular Research Updates of mTOR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Biotechnology Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Peptides to Target Tumor Vasculature and Lymphatics for Improved Anti-Angiogenesis Therapy
Current Cancer Drug Targets Optimizing Anti-EGFR Strategies in Cancer Treatment
Current Cancer Therapy Reviews Outlook on Epigenetic Therapeutic Approaches for Treatment of Gastric Cancer
Current Cancer Drug Targets Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Stimulation of Peroxisome Proliferator-Activated Receptor-Gamma (PPARγ) using Pioglitazone Decreases the Survival of Acute Promyelocytic Leukemia Cells through Up-Regulation of PTEN Expression
Anti-Cancer Agents in Medicinal Chemistry EGFR(s) in Aging and Carcinogenesis of the Gastrointestinal Tract
Current Protein & Peptide Science HIF-1 Signaling in Drug Resistance to Chemotherapy
Current Medicinal Chemistry The Effect of Flubendazole on Adhesion and Migration in SW480 and SW620 Colon Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Recent Progress of Small Molecular VEGFR Inhibitors as Anticancer Agents
Mini-Reviews in Medicinal Chemistry Long Non-Coding RNAs As Epigenetic Regulators in Cancer
Current Pharmaceutical Design